Implementation of the Randomized Embedded Multifactorial Adaptive Platform for COVID-19 (REMAP-COVID) trial in a US health system—lessons learned and recommendations

Table 1 REMAP-COVID domains and arms. Additional domains can be found at www.remapcap.org

Domain	Arms
Antiviral^a	Hydroxychloroquine	Usual care
Corticosteroids^a	Low dose hydrocortisone	Moderate dose hydrocortisone	Usual care
Immunoglobulin^b	Convalescent plasma	Usual care	Monoclonal antibodies
Therapeutic Anticoagulation^b	Full dose anticoagulation (DVT/PE)	Thromboprophylaxis
Vitamin C^b	High dose vitamin C	Usual care
Immune Modulation 2 (IM2)^b,c	Eritoran^c	Apremilast^c	Usual care
Platelet Inhibition^d	P2Y12 inhibitor	Aspirin	Usual care
Statins^d	Simvastatin	Usual care
ACE2 RAS Modulation^d	ACE inhibitor	ARB^e	Usual care
Mechanical Ventilation^d	Protocolized mechanical ventilation	Usual care

DVT/PE deep vein thrombosis/pulmonary embolus, IND Investigational New Drug, IRB Institutional Review Board, ACE angiotensin-converting enzyme inhibitor, ARB angiotensin receptor blocker
^aDomain closed in the USA
^bDomain actively enrolling in the USA, in partnership with the ATTACC and ACTIV4a (therapeutic anticoagulation), and LOVIT (Vitamin C) trials
^cEnrolling as an IND domain under FDA oversight
^dProtocol in development or pending activation
^eA fourth arm of an ARB with a chemokine receptor-2 inhibitor may also be offered

ISSN: 1745-6215